BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nirogi R, Bhyrapuneni G, Muddana NR, Manoharan A, Shinde AK, Mohammed AR, Padala NP, Ajjala DR, Subramanian R, Palacharla VRC. Absorption, distribution, metabolism, excretion (ADME), drug-drug interaction potential and prediction of human pharmacokinetics of SUVN-G3031, a novel histamine 3 receptor (H3R) inverse agonist in clinical development for the treatment of narcolepsy. European Journal of Pharmaceutical Sciences 2020;152:105425. [DOI: 10.1016/j.ejps.2020.105425] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Wang K, Ding J, Li X, Guo W, Zhu X, Su Y, Sun L, Zhou H, Ding L. Effects of itraconazole and rifampicin on the pharmacokinetics and safety of youkenafil, a novel phosphodiesterase type 5 inhibitor, in healthy Chinese subjects. European Journal of Pharmaceutical Sciences 2022. [DOI: 10.1016/j.ejps.2022.106213] [Reference Citation Analysis]
2 Rodriguez-fernandez K, Gras-colomer E, Climente-martí M, Mangas-sanjuán V, Merino-sanjuan M. Pharmacometric characterization of entero-hepatic circulation processes of orally administered formulations of amiodarone under complex binding kinetics. European Journal of Pharmaceutical Sciences 2022. [DOI: 10.1016/j.ejps.2022.106198] [Reference Citation Analysis]
3 Nirogi R, Mohammed AR, Shinde AK, Gagginapally SR, Kancharla DM, Ravella SR, Bogaraju N, Middekadi VR, Subramanian R, Palacharla RC, Benade V, Muddana N, Abraham R, Medapati RB, Thentu JB, Mekala VR, Petlu S, Lingavarapu BB, Yarra S, Kagita N, Goyal VK, Pandey SK, Jasti V. Discovery and Preclinical Characterization of Usmarapride (SUVN-D4010): A Potent, Selective 5-HT4 Receptor Partial Agonist for the Treatment of Cognitive Deficits Associated with Alzheimer's Disease. J Med Chem 2021;64:10641-65. [PMID: 34251799 DOI: 10.1021/acs.jmedchem.1c00703] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
4 Pang YY, Li JD, Gao L, Yang X, Dang YW, Lai ZF, Liu LM, Yang J, Wu HY, He RQ, Huang ZG, Xiong DD, Yang LH, Shi L, Mo WJ, Tang D, Lu HP, Chen G. The clinical value and potential molecular mechanism of the downregulation of MAOA in hepatocellular carcinoma tissues. Cancer Med 2020;9:8004-19. [PMID: 32931665 DOI: 10.1002/cam4.3434] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]